The Soluble Interleukin 6 Receptor: Advanced Therapeutic Options in Inflammation

Clinical Pharmacology and Therapeutics

Volumn 102, Issue 4, 2017, Pages 591-598

  Rose John, Stefan ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CORTISONE; GLYCOPROTEIN GP 130; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; METHOTREXATE; OLAMKICEPT; SOLUBLE GLYCOPROTEIN GP 130FC; SOLUBLE INTERLEUKIN 6 RECEPTOR; UNCLASSIFIED DRUG; HYBRID PROTEIN; SGP130FC PROTEIN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL INFECTION; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; DRUG DESIGN; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; PATHOLOGY;

ANIMALS; CYTOKINE RECEPTOR GP130; DRUG DESIGN; HUMANS; INFLAMMATION; INTERLEUKIN-6; RECEPTORS, INTERLEUKIN-6; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION;

EID: 85026447702     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.782     Document Type: Article

References (80)

1. Rose-John, S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int. J. Biol. Sci. 8, 1237–1247 (2012).
2. Hirano, T. et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324, 73–76 (1986).
3. Gauldie, J., Richards, C., Harnish, D., Lansdorp, P. & Baumann, H. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc. Natl. Acad. Sci. U S A 84, 7251–7255 (1987).
4. Brakenhoff, J.P., de Groot, E.R., Evers, R.F., Pannekoek, H. & Aarden, L.A. Molecular cloning and expression of hybridoma growth factor in Escherichia coli. J. Immunol. 139, 4116–4121 (1987).
5. Zilberstein, A., Ruggieri, R., Korn, J.H. & Revel, M. Structure and expression of cDNA and genes for human interferon-beta-2, a distinct species inducible by growth-stimulatory cytokines. EMBO J. 5, 2529–2537 (1986).
6. Haegeman, G., Content, J., Volckaert, G., Derynck, R., Tavernier, J. & Fiers, W. Structural analysis of the sequence coding for an inducible 26-kDa protein in human fibroblasts. Eur. J. Biochem. 159, 625–632 (1986).
7. Jones, S.A., Scheller, J. & Rose-John, S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J. Clin. Invest. 121, 3375–3383 (2011).
8. Schaper, F. & Rose-John, S. Interleukin-6: Biology, signaling and strategies of blockade. Cytokine Growth Factor Rev. 26, 475–487 (2015).
9. Scheller, J., Chalaris, A., Schmidt-Arras, D. & Rose-John, S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim. Biophys. Acta 1813, 878–888 (2011).
10. van Dam, M. et al. Structure-function analysis of interleukin-6 utilizing human/murine chimeric molecules. Involvement of two separate domains in receptor binding. J. Biol. Chem. 268, 15285–15290 (1993).
11. Kruttgen, A. et al. The three carboxy-terminal amino acids of human interleukin-6 are essential for its biological activity. FEBS Lett. 273, 95–98 (1990).
12. Ehlers, M. et al. Identification of two novel regions of human IL-6 responsible for receptor binding and signal transduction. J. Immunol. 153, 1744–1753 (1994).
13. Brakenhoff, J.P. et al. Development of a human interleukin-6 receptor antagonist. J. Biol. Chem. 269, 86–93 (1994).
14. Savino, R. et al. Generation of interleukin-6 receptor antagonists by molecular-modeling guided mutagenesis of residues important for gp130 activation. EMBO J. 13, 1357–1367 (1994).
15. Mullberg, J. et al. The soluble interleukin-6 receptor is generated by shedding. Eur. J. Immunol. 23, 473–480 (1993).
16. Mullberg, J., Schooltink, H., Stoyan, T., Heinrich, P.C. & Rose-John, S. Protein kinase C activity is rate limiting for shedding of the interleukin-6 receptor. Biochem. Biophys. Res. Commun. 189, 794–800 (1992).
17. Rose-John, S., Dietrich, A. & Marks, F. Molecular cloning of mouse protein kinase C (PKC) cDNA from Swiss 3T3 fibroblasts. Gene 74, 465–471 (1988).
18. Chalaris, A. et al. Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood 110, 1748–1755 (2007).
19. Mullberg, J. et al. The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site. J. Immunol. 152, 4958–4968 (1994).
20. Matthews, V. et al. Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J. Biol. Chem. 278, 38829–38839 (2003).
21. Riethmueller, S. et al. Proteolytic origin of the soluble human IL-6R in vivo and a decisive role of N-glycosylation. PLoS Biol. 15, e2000080 (2017).
22. Riethmueller, S. et al. Cleavage site localization differentially controls interleukin-6 receptor proteolysis by ADAM10 and ADAM17. Sci. Rep. 6, 25550 (2016).
23. Lust, J.A., Donovan, K.A., Kline, M.P., Greipp, P.R., Kyle, R.A. & Maihle, N.J. Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine 4, 96–100 (1992).
24. Schumacher, N. et al. Shedding of endogenous interleukin-6 receptor (IL-6R) is governed by a disintegrin and metalloproteinase (ADAM) proteases while a full-length IL-6R isoform localizes to circulating microvesicles. J. Biol. Chem. 290, 26059–26071 (2015).
25. Rose-John, S. & Heinrich, P.C. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem. J. 300, 281–290 (1994).
26. Rose-John, S. The soluble interleukin-6 receptor and related proteins. Best Pract. Res. Clin. Endocrinol. Metab. 29, 787–797 (2015).
27. Oberg, H.H., Wesch, D., Grussel, S., Rose-John, S. & Kabelitz, D. Differential expression of CD126 and CD130 mediates different STAT-3 phosphorylation in CD4+CD25- and CD25high regulatory T cells. Int. Immunol. 18, 555–563 (2006).
28. Rose-John, S. et al. Studies on the structure and regulation of the human hepatic interleukin-6 receptor. Eur. J. Biochem. 190, 79–83 (1990).
29. Fischer, M. et al. I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat. Biotechnol. 15, 142–145 (1997).
30. Calabrese, L.H. & Rose-John, S. IL-6 biology: implications for clinical targeting in rheumatic disease. Nat. Rev. Rheumatol. 10, 720–727 (2014).
31. Marz, P., Ozbek, S., Fischer, M., Voltz, N., Otten, U. & Rose-John, S. Differential response of neuronal cells to a fusion protein of ciliary neurotrophic factor/soluble CNTF-receptor and leukemia inhibitory factor. Eur. J. Biochem. 269, 3023–3031 (2002).
32. Islam, O., Gong, X., Rose-John, S. & Heese, K. Interleukin-6 and neural stem cells: more than gliogenesis. Mol. Biol. Cell 20, 188–199 (2009).
33. Audet, J., Miller, C.L., Rose-John, S., Piret, J.M. & Eaves, C.J. Distinct role of gp130 activation in promoting self-renewal divisions by mitogenically stimulated murine hematopoietic stem cells. Proc. Natl. Acad. Sci. U S A 98, 1757–1762 (2001).
34. Klouche, M., Bhakdi, S., Hemmes, M. & Rose-John, S. Novel path to activation of vascular smooth muscle cells: up-regulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor. J. Immunol. 163, 4583–4589 (1999).
35. Viswanathan, S., Benatar, T., Rose-John, S., Lauffenburger, D.A. & Zandstra, P.W. Ligand/receptor signaling threshold (LIST) model accounts for gp130-mediated embryonic stem cell self-renewal responses to LIF and HIL-6. Stem Cells 20, 119–138 (2002).
36. Humphrey, R.K. et al. Maintenance of pluripotency in human embryonic stem cells is STAT3 independent. Stem Cells 22, 522–530 (2004).
37. Jostock, T. et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur. J. Biochem. 268, 160–167 (2001).
38. Rabe, B. et al. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 111, 1021–1028 (2008).
39. Rothaug, M., Becker-Pauly, C. & Rose-John, S. The role of interleukin-6 signaling in nervous tissue. Biochim. Biophys. Acta 1863, 1218–1227 (2016).
40. Stuhlmann-Laeisz, C. et al. Forced dimerization of gp130 leads to constitutive STAT3 activation, cytokine-independent growth, and blockade of differentiation of embryonic stem cells. Mol. Biol. Cell 17, 2986–2995 (2006).
41. Dechow, T. et al. GP130 activation induces myeloma and collaborates with MYC. J. Clin. Invest. 124, 5263–5274 (2014).
42. Peters, M. et al. Extramedullary expansion of hematopoietic progenitor cells in interleukin (IL)-6-sIL-6R double transgenic mice. J. Exp. Med. 185, 755–766 (1997).
43. Peters, M., Blinn, G., Solem, F., Fischer, M., Meyer zum Buschenfelde, K.H. & Rose-John, S. In vivo and in vitro activities of the gp130-stimulating designer cytokine Hyper-IL-6. J. Immunol. 161, 3575–3581 (1998).
44. Garbers, C., Aparicio-Siegmund, S. & Rose-John, S. The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition. Curr. Opin. Immunol. 34, 75–82 (2015).
45. Waage, A., Brandtzaeg, P., Halstensen, A., Kierulf, P. & Espevik, T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. J. Exp. Med. 169, 333–338 (1989).
46. Scheller, J. & Rose-John, S. The interleukin 6 pathway and atherosclerosis. Lancet 380, 338 (2012).
47. Garbers, C. et al. The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases. Biochim. Biophys. Acta 1842, 1485–1494 (2014).
48. Ferreira, R.C. et al. Functional IL6R 358Ala allele impairs classical IL-6 receptor signaling and influences risk of diverse inflammatory diseases. PLoS Genet. 9, e1003444 (2013).
49. Tanaka, T., Narazaki, M., Ogata, A. & Kishimoto, T. A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy. Semin. Immunol. 26, 88–96 (2014).
50. Rose-John, S., Winthrop, K.L. & Calabrese, L.H. The role of IL-6 in host defense against infections: Immunobiology and Clinical Implications. Nat. Rev. Rheumatol. (2017) [Epub ahead of print].
51. Gabay, C. et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 381, 1541–1550 (2013).
52. Feldmann, M. & Steinman, L. Design of effective immunotherapy for human autoimmunity. Nature 435, 612–619 (2005).
53. Breedveld, F. TNF antagonists opened the way to personalized medicine in rheumatoid arthritis. Mol. Med. 20(suppl. 1), S7–9 (2014).
54. Sodenkamp, J. et al. Therapeutic targeting of interleukin-6 trans-signaling does not affect the outcome of experimental tuberculosis. Immunobiology 217, 996–1004 (2012).
55. Hoge, J. et al. IL-6 controls the innate immune response against Listeria monocytogenes via classical IL-6 signaling. J. Immunol. 190, 703–711 (2013).
56. Garbers, C. et al. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J. Biol. Chem. 286, 42959–42970 (2011).
57. Atreya, R. et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat. Med. 6, 583–588 (2000).
58. Mitsuyama, K. et al. STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice. Gut 55, 1263–1269 (2006).
59. Lesina, M. et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19, 456–469 (2011).
60. Goumas, F.A. et al. Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer. Int. J. Cancer 137, 1035–1046 (2015).
61. Wei, L.H. et al. The role of IL-6 trans-signaling in vascular leakage: implications for ovarian hyperstimulation syndrome in a murine model. J. Clin. Endocrinol. Metab. 98, E472–484 (2013).
62. Nowell, M.A. et al. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J. Immunol. 171, 3202–3209 (2003).
63. Richards, P.J. et al. Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. Arthritis Rheum. 54, 1662–1672 (2006).
64. Tsantikos, E. et al. Interleukin-6 trans-signaling exacerbates inflammation and renal pathology in lupus-prone mice. Arthritis Rheum. 65, 2691–2702 (2013).
65. Doganci, A. et al. The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo. J. Clin. Invest. 115, 313–325 (2005).
66. Ullah, M.A. et al. Allergen-induced IL-6 trans-signaling activates gammadelta T cells to promote type 2 and type 17 airway inflammation. J. Allergy Clin. Immunol. 136, 1065–1073 (2015).
67. Barkhausen, T. et al. Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model. Crit. Care Med. 39, 1407–1413 (2011).
68. Greenhill, C.J. et al. IL-6 trans-signaling modulates TLR4-dependent inflammatory responses via STAT3. J. Immunol. 186, 1199–1208 (2011).
69. Campbell, I.L. et al. Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain. J. Neurosci. 34, 2503–2513 (2014).
70. Luig, M. et al. Inflammation-induced IL-6 functions as a natural brake on macrophages and limits GN. J. Am. Soc. Nephrol. 26, 1597–1607 (2015).
71. Braun, G.S. et al. IL-6 trans-signaling drives murine crescentic GN. J. Am. Soc. Nephrol. 27, 132–142 (2016).
72. Schuett, H. et al. Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol. 32, 281–290 (2012).
73. Kraakman, M.J. et al. Blocking IL-6 trans-signaling prevents high-fat diet-induced adipose tissue macrophage recruitment but does not improve insulin resistance. Cell Metab. 21, 403–416 (2015).
74. Lo, C.W. et al. IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer Res. 71, 424–434 (2011).
75. Zhang, H. et al. IL-6 trans-signaling promotes pancreatitis-associated lung injury and lethality. J. Clin. Invest. 123, 1019–1031 (2013).
76. Brooks, G.D. et al. IL6 trans-signaling promotes KRAS-driven lung carcinogenesis. Cancer Res. 76, 866–876 (2016).
77. Bergmann, J. et al. IL-6 trans-signaling is essential for the development of hepatocellular carcinoma in mice. Hepatology 65, 89–103 (2017).
78. Ruwanpura, S.M. et al. Therapeutic targeting of the IL-6 trans-signalling/mTORC1 axis in pulmonary emphysema. Am. J. Respir. Crit. Care Med. (2016) [Epub ahead of print].
79. Grivennikov, S. et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15, 103–113 (2009).
80. Matsumoto, S. et al. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J. Immunol. 184, 1543–1551 (2010).